穿透性房角成形术治疗外伤性房角后退性青光眼患者的临床结局:一项前瞻性干预性病例系列研究
前瞻性干预性病例系列研究纳入40例(40眼)外伤性房角后退性青光眼患者,行穿透性房角成形术。完全成功者术前平均眼压37.8±12.3 mm Hg、用3.3±1.2种降眼压药,术后12个月降至14.8±3.6 mm Hg、用0.1±0.5种药(p<0.05);6个月完全成功率87.5%(35/40眼),12个月89.5%(34/38眼)。结论认为该术式显著降低眼压且成功率高。
要点
- 穿透性房角成形术经角膜巩膜床开窗建立前房至Schlemm管口的直接引流通路,不使用抗代谢药物。
- 完全成功者术后12个月平均眼压14.8±3.6 mm Hg、平均用0.1±0.5种降眼压药,均低于术前(p<0.05)。
- 前房积血(18/40,45.0%)和一过性眼压升高≥30 mm Hg(9/40,22.5%)为最常见术后并发症。
核心结论
- 穿透性房角成形术可显著降低房角后退性青光眼患者的眼压,并具有较高的成功率。
研究设计与样本
- 前瞻性干预性病例系列研究,纳入40例(40眼)外伤性房角后退性青光眼患者,均行穿透性房角成形术并完成环形导管置入。
- 穿透性房角成形术是一种新的基于Schlemm管的眼内引流手术,经角膜巩膜床开窗建立前房至Schlemm管口的直接引流通路,不使用抗代谢药物。
- 评估术后眼压、降眼压药物数量及手术相关并发症;成功定义为眼压≤21 mm Hg,不用药为完全成功、用药为条件成功。
- 试验注册号:ChiCTR1900020511。
主要发现
- 患者平均年龄42±13岁。
- 完全成功者术前平均眼压37.8±12.3 mm Hg、用3.3±1.2种降眼压药;术后1、3、6、12个月平均眼压分别为18.5±6.4、14.9±4.6、15.7±5.4、14.8±3.6 mm Hg,平均用药分别为1.2±1.4、0.1±0.5、0.1±0.4、0.1±0.5种(p<0.05)。
- 完全成功率6个月为35/40眼(87.5%),12个月为34/38眼(89.5%)。
- 最常见术后并发症为前房积血(18/40,45.0%)和一过性眼压升高≥30 mm Hg(9/40,22.5%)。
关键数值与推荐
- 成功定义:眼压≤21 mm Hg,不用降眼压药为完全成功,用药为条件成功。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIM: To evaluate the clinical outcomes of penetrating canaloplasty in traumatic angle recession glaucoma at 1 year. METHODS: Patients with angle recession glaucoma underwent penetrating canaloplasty, a new Schlemm's canal-based internal drainage procedure, which creates a direct canal for flow of aqueous humour from the anterior chamber to the ostia of Schlemm's canal via a window created at the corneal scleral bed without use of antimetabolites. Postoperative intraocular pressure (IOP), number of glaucoma medications, and procedure-related complications were evaluated. Success was defined as an IOP ≤21 mm Hg without (complete) or with (qualified) use of glaucoma medication. RESULTS: Forty eyes in 40 patients with angle recession glaucoma underwent successful circumferential catheterisation. The mean patient age was 42±13 years. In patients with penetrating canaloplasty that was deemed to be completely successful, the mean IOP decreased from a preoperative value of 37.8±12.3 mm Hg on 3.3±1.2 anti-glaucoma medications to 18.5±6.4 mm Hg on 1.2±1.4 medications, 14.9±4.6 mm Hg on 0.1±0.5 medications, 15.7±5.4 mm Hg on 0.1±0.4 medications and 14.8±3.6 mm Hg on 0.1±0.5 medications at 1, 3, 6 and 12 months postoperatively (p<0.05). Complete success was achieved in 35/40 eyes (87.5%) at 6 months and in 34/38 (89.5%) at 12 months. Hyphema (18/40, 45.0%) and transient IOP elevation (≥30 mm Hg, 9/40, 22.5%) were the most common postoperative complications. CONCLUSION: Penetrating canaloplasty significantly reduces IOP and has a high success rate in angle recession glaucoma. TRIAL REGISTRATION NUMBER: ChiCTR1900020511.
引用
- Cheng H, Ye W, Zhang S, et al. Clinical outcomes of penetrating canaloplasty in patients with traumatic angle recession glaucoma: a prospective interventional case series. Br J Ophthalmol. 2022. PMID: 35318223. doi:10.1136/bjophthalmol-2021-320659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。